Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author ARELLANO, I.
CESTARI, T.
OCAMPO-CANDIANI, J.
AZULAY-ABULAFIA, L.
TRINDADE NETO, P. Bezerra
HEXSEL, D.
MACHADO-PINTO, J.
MUNOZ, H.
RIVITTI-MACHADO, M. C. FMUSP-HC
SITTART, A.
ALMEIDA, A. R. Trindade de
REGO, V.
PALIARGUES, F.
MARQUES-HASSUN, K.
dc.date.issued 2012
dc.identifier.citation JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, v.26, n.5, p.611-618, 2012
dc.identifier.issn 0926-9959
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/1332
dc.description.abstract Background The relapsing nature of melasma emphasizes the need to maintain efficacy achieved after acute treatment. Objective To compare clinical efficacy and safety of two 6-month Triple Combination (TC; containing fluocinolone acetonide, hydroquinone and tretinoin) maintenance regimens in subjects with moderate to severe melasma, after daily treatment up to 8 weeks. Methods This randomized, investigator-blinded, controlled study had a maintenance phase of 6 months. Sixteen centres in Brazil and Mexico enrolled 242 subjects 18 years or older attaining no or mild melasma after 8 weeks of daily TC applications. Subjects were randomized to receive TC in a twice weekly or tapering regimen [3/week (1st month), 2/week (2nd month), 1/week (4th month)]. Efficacy and safety measurements included median time to relapse and relapse-free rate, Global Severity Score, Melasma Area and Severity Index score (MASI), subject's assessment, quality of life questionnaire (MelasQol), and adverse events. Results The majority (78.8%) had no or mild melasma (GSS <= 1) at week 8 and entered maintenance phase. After 6 months, 53% of patients remained relapse-free with improved quality of life, and time to relapse was similar between groups (about 190 days). Melasma severity at study entry, not maintenance baseline, influenced relapse rate. The twice weekly regimen tended to show better effectiveness in postponing relapse in severe melasma. Both regimens were safe. Conclusions After resolution of melasma with TC, maintenance therapy over 6 months was successful in preventing relapse in over half of the patients who entered maintenance phase. Prescribing medicines should be adapted to patients based on melasma severity.
dc.language.iso eng
dc.publisher WILEY-BLACKWELL
dc.relation.ispartof Journal of the European Academy of Dermatology and Venereology
dc.rights restrictedAccess
dc.subject.other of-life questionnaire; retinoic acid; validation; tretinoin; therapy; skin; hydroquinone; efficacy; language; safety
dc.title Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity
dc.type article
dc.rights.holder Copyright WILEY-BLACKWELL
dc.identifier.doi 10.1111/j.1468-3083.2011.04135.x
dc.identifier.pmid 21623930
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author RIVITTI-MACHADO, M. C.:HC:ICHC
hcfmusp.author.external · ARELLANO, I.:Hosp Gen Mexico OPD, Mexico City, DF, Mexico
· CESTARI, T.:Univ Rio Grande Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil
· OCAMPO-CANDIANI, J.:Hosp Univ Jose E Gonzalez, Monterrey, Mexico
· AZULAY-ABULAFIA, L.:Inst Dermatol & Estet Rio de Janeiro, Rio De Janeiro, Brazil
· TRINDADE NETO, P. Bezerra:Hosp Univ Onofre Lopes, Petropolis, Brazil
· SITTART, A.:Hosp Servidor Publ Estado Sao Paulo, Sao Paulo, Brazil
· ALMEIDA, A. R. Trindade de:Hosp Servidor Publ Municipal Sao Paulo, Sao Paulo, Brazil
· REGO, V.:Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil
· MARQUES-HASSUN, K.:Univ Fed Sao Paulo, Sao Paulo, Brazil
hcfmusp.origem.id 2-s2.0-84860224279
hcfmusp.origem.id WOS:000303051300011
hcfmusp.publisher.city MALDEN
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Balkrishnan R, 2003, BRIT J DERMATOL, V149, P572, DOI 10.1046/j.1365-2133.2003.05419.x
· Barankin B, 2002, J CUTAN MED SURG, V6, P236, DOI 10.1007/s10227-001-0045-240
· Bhawan J, 2009, AM J DERMATOPATH, V31, P794, DOI 10.1097/DAD.0b013e3181a9070d
· Cestari T, 2009, J EUR ACAD DERMATOL, V23, P760, DOI 10.1111/j.1468-3083.2009.03251.x
· Cestari TF, 2006, BRIT J DERMATOL, V156, P13, DOI 10.1111/j.1365-2133.2006.07591.x
· Dominguez AR, 2006, J AM ACAD DERMATOL, V55, P59, DOI 10.1016/j.jaad.2006.01.049
· GANO SE, 1979, CUTIS, V23, P239
· Giannotti B, 1995, CLIN DRUG INVEST S2, V10, P57
· Grimes PE, 2010, J AM ACAD DERMATOL, V62, P962, DOI 10.1016/j.jaad.2009.06.067
· Javaheri SN, 2001, INT J DERMATOL, V40, P354, DOI 10.1046/j.1365-4362.2001.01149.x
· Kang WH, 1998, J DERMATOL, V25, P87
· Katsambas A, 1995, J EUR ACAD DERMATOL, V4, P217, DOI 10.1111/j.1468-3083.1995.tb00341.x
· KIMBROUGHGREEN CK, 1994, ARCH DERMATOL, V130, P727, DOI 10.1001/archderm.130.6.727
· KLIGMAN AM, 1975, ARCH DERMATOL, V111, P40, DOI 10.1001/archderm.111.1.40
· Mosher DB, 1999, FITZPATRICKS DERMATO, V1, P945
· Ortonne JP, 2009, J EUR ACAD DERMATOL, V23, P1254, DOI 10.1111/j.1468-3083.2009.03295.x
· Pandya AG, 2000, DERMATOL CLIN, V18, P91, DOI 10.1016/S0733-8635(05)70150-9
· Pandya AG, 2011, J AM ACAD DERMATOL, V64, P78, DOI 10.1016/j.jaad.2009.10.051
· PATHAK MA, 1986, J AM ACAD DERMATOL, V15, P894, DOI 10.1016/S0190-9622(86)70247-8
· Taylor SC, 2003, CUTIS, V72, P67
· Torok Helen, 2005, J Drugs Dermatol, V4, P592
· Vasquez M, 1983, CUTIS, V32, P92
dc.description.index MEDLINE
hcfmusp.citation.scopus 12
hcfmusp.citation.wos 6
hcfmusp.affiliation.country Brasil
hcfmusp.affiliation.country México


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics